State of Alaska Department of Revenue Purchases 1,337 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

State of Alaska Department of Revenue lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.0% during the 4th quarter, Holdings Channel reports. The firm owned 134,346 shares of the biotechnology company’s stock after buying an additional 1,337 shares during the quarter. State of Alaska Department of Revenue’s holdings in ADMA Biologics were worth $2,304,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ADMA. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics in the 3rd quarter worth about $30,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the 3rd quarter worth about $31,000. GAMMA Investing LLC grew its holdings in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the last quarter. National Bank of Canada FI bought a new stake in ADMA Biologics during the 3rd quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in ADMA Biologics during the 3rd quarter worth about $62,000. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ADMA. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $16.66 on Tuesday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The company has a market cap of $3.94 billion, a PE ratio of 59.50 and a beta of 0.75. The company’s 50-day moving average is $17.64 and its two-hundred day moving average is $17.72.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.